RT Journal Article
SR Electronic
T1 Seroprevalence and attainment of herd immunity against SARS CoV-2: A modelling study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.22.21250328
DO 10.1101/2021.01.22.21250328
A1 Paul, Abhijit
A1 Kadnur, Harshith B
A1 Ray, Animesh
A1 Chatterjee, Samrat
A1 Wig, Naveet
YR 2021
UL http://medrxiv.org/content/early/2021/01/29/2021.01.22.21250328.abstract
AB Objective The present study is aims to predict the likelihood of and likely time required to attain herd immunity against COVID-19 in New Delhi due to natural infection.Method An ODE based mathematical model was constructed by extending the classical SEIR model to predict the seroprevalence rate in Delhi. We estimated the parameter values for Delhi using available data (reported cases and the seroprevalence rate) and used them for future prediction. We also attempted to capture the changes in the seroprevalence rate with different possibilities of reinfection.Results Maximum seroprevalence rate obtained through our model is 31.65% and also a reduction in the seroprevalence rate was observed for the upcoming one month (month of January, 2021) due to the reduced transmission rate. After increasing the transmission rate to the value same as the third wave in New Delhi, we obtained a maximum value of 54.96%. This maximum value significantly decreased with the reduction in the reinfection possibilities. Also, a little impact of the duration of persistence of antibodies, 180 vs 105 days, was observed on the maximum seroprevalence.Conclusion This modelling study suggests that natural infection alone, as gauged by serial sero-surveys, will not result in attainment of herd immunity in the state of Delhi.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding has been received for this modelling studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Appropriate research reporting guidelines have been followedAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo data is included as it is a modelling study